Short Interest in Cingulate Inc. (NASDAQ:CING) Decreases By 22.4%
Short Interest in Cingulate Inc. (NASDAQ:CING) Decreases By 22.4%
Cingulate Inc. (NASDAQ:CING – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 82,100 shares, a decline of 22.4% from the December 15th total of 105,800 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 50,600 shares, the short-interest ratio is presently 1.6 days.
纳斯达克(CDH：Cing-Get Rating)12月份空头股数股价大幅下跌。截至12月30日，空头股数共有82,100股，较12月15日的105,800股下降了22.4%。目前，该公司1.1%的股份被卖空。以日均成交量50,600股计算，目前短息比率为1.6天。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of equities analysts have weighed in on the stock. Ascendiant Capital Markets assumed coverage on shares of Cingulate in a research report on Monday, October 3rd. They set a "buy" rating for the company. HC Wainwright reiterated a "buy" rating on shares of Cingulate in a research report on Tuesday. Finally, Maxim Group assumed coverage on shares of Cingulate in a research report on Tuesday, November 22nd. They issued a "buy" rating for the company.
许多股票分析师对该股进行了加码。上升资本市场在10月3日星期一的一份研究报告中对Cingate的股票进行了报道。他们为该公司设定了“买入”评级。周二，HC Wainwright在一份研究报告中重申了对cingate股票的“买入”评级。最后，Maxim Group在11月22日星期二的一份研究报告中对Cingate的股票进行了报道。他们对该公司的评级为“买入”。
Insider Activity at Cingulate
Cingate的内幕活动
In other news, Director Peter J. Werth bought 28,934 shares of the firm's stock in a transaction that occurred on Tuesday, December 13th. The stock was purchased at an average cost of $0.98 per share, for a total transaction of $28,355.32. Following the purchase, the director now directly owns 975,165 shares in the company, valued at approximately $955,661.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Gregg Wm Givens acquired 85,000 shares of Cingulate stock in a transaction on Tuesday, November 22nd. The stock was bought at an average cost of $0.88 per share, for a total transaction of $74,800.00. Following the completion of the transaction, the director now owns 154,318 shares of the company's stock, valued at approximately $135,799.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter J. Werth acquired 28,934 shares of Cingulate stock in a transaction on Tuesday, December 13th. The shares were bought at an average price of $0.98 per share, with a total value of $28,355.32. Following the completion of the transaction, the director now directly owns 975,165 shares of the company's stock, valued at approximately $955,661.70. The disclosure for this purchase can be found here. Insiders bought a total of 141,388 shares of company stock worth $129,998 in the last three months. Company insiders own 31.28% of the company's stock.
其他新闻方面，董事彼得·韦斯在12月13日(星期二)的一笔交易中购买了28,934股该公司股票。这只股票是以每股0.98美元的平均成本购买的，总交易额为28,355.32美元。收购完成后，董事现在直接拥有该公司975,165股票，价值约955,661.70美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接。在相关新闻中，董事Gregg Wm Givens在11月22日(星期二)的一笔交易中收购了85,000股彩虹股票。这只股票的平均价格为每股0.88美元，总成交额为74,800.00美元。交易完成后，董事现在拥有该公司154,318股股票，价值约135,799.84美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。此外，董事彼得·J·韦斯在12月13日(星期二)的一次交易中收购了28,934股彩虹股票。这些股票是以每股0.98美元的平均价格购买的，总价值为28,355.32美元。交易完成后，董事现在直接拥有975,165股该公司股票，价值约955,661.70美元。关于这次购买的披露可以找到这里。在过去的三个月里，内部人士总共购买了141,388股公司股票，价值129,998美元。公司内部人士持有该公司31.28%的股份。
Institutional Trading of Cingulate
扣带的机构性交易
Cingulate Price Performance
扣带性价比
Shares of CING traded up $0.03 during mid-day trading on Friday, reaching $0.98. The stock had a trading volume of 45,234 shares, compared to its average volume of 72,641. Cingulate has a 52-week low of $0.66 and a 52-week high of $2.48. The business's fifty day moving average is $0.96 and its 200 day moving average is $1.21. The firm has a market cap of $11.03 million and a price-to-earnings ratio of -0.66.
在周五午盘交易中，CING的股价上涨了0.03美元，达到0.98美元。该股成交量为45,234股，而其平均成交量为72,641股。Cingate的52周低点为0.66美元，52周高位为2.48美元。该业务的50日移动均线切入位为0.96美元，200日移动均线切入位为1.21美元。该公司市值为1103万美元，市盈率为-0.66倍。
Cingulate (NASDAQ:CING – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.36) earnings per share (EPS) for the quarter.
纳斯达克(纳斯达克：Cing-Get Rating)最近一次发布季度收益报告是在11月14日(周一)。该公司公布了该季度每股收益(EPS)(0.36美元)。
About Cingulate
关于扣带
(Get Rating)
(获取评级)
Cingulate Inc, a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders.
Cingate Inc.是一家临床阶段的生物制药公司，专注于开发治疗注意力缺陷/多动障碍的候选产品。该公司的主要候选产品是处于第三阶段临床试验的CTX-1301(醋酸地塞米酯)和用于治疗注意力缺陷/多动障碍的CTX-1302(右旋苯丙胺)。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Cingulate (CING)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取StockNews.com关于Cingate的研究报告(CING)
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车？
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票：在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
接受《扣带日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cingate及相关公司的最新新闻和分析师评级的每日简要摘要。